<DOC>
	<DOCNO>NCT00937131</DOCNO>
	<brief_summary>TTP rare serious blood disorder , characterize formation small clot ( micro thrombus ) within circulation fatal . The formation blood clot occur primarily small blood vessel , arteriole capillary , associate multisystem organ involvement , especially brain kidney . TTP incidence approximately 1-3 people/million population/year . TTP due decrease enzyme , ADAMTS 13 release cell line blood vessel ( endothelial cell ) . ADAMTS 13 'cleaves ' break large von Willebrand Factor ( vWF ) strand . vWF use blood clotting . Deficiency inhibition enzyme , result release ultra large vWF circulation . Platelets bind ultra large vWF multimers , promote blood clot formation platelet consumption ( thrombocytopenia ) . In 70 % TTP case precipitate cause find majority patient antibody ADAMTS 13 . Plasma Exchange ( PEX ) introduce management TTP 1977 mortality TTP patient since decrease approximately 90 % 15-20 % . PEX essential TTP treatment plasma contain miss enzyme ADAMTS 13 . Rituximab ( license internationally used monoclonal antibody ) selectively act white blood cell know B-lymphocytes B cell produce antibody ADAMTS 13 . By inhibit ADAMTS 13 antibody production , ADAMTS 13 activity increase , result remission . Rituximab use institution patient acute TTP refractory standard treatment - PEX . The result remission dramatic , non-toxic side effect profile patient date relapse ( long follow-up 19 month ) follow Rituximab therapy . Therefore , plan use Rituximab PEX patient present acute TTP .</brief_summary>
	<brief_title>The Use Rituximab Acute Thrombotic Thrombocytopenic Purpura ( TTP )</brief_title>
	<detailed_description>This multi-centre study within South East England ( SEE ) Thrombotic Thrombocytopenic Purpura ( TTP ) study group , primarily involve tertiary centre expertise treat TTP , apheresis unit specialist medical professional . Feedback discussion TTP patient treatment discussion attend out-patient clinic incorporate development study . We review treatment protocol TTP patient publish peer review journal consult SEE TTP study group study design . Medical professional expertise TTP treatment management also consult . This non-randomised Phase feasibility study ass ( ) whether Rituximab PEX decrease time remission patient acute TTP , ( ii ) mortality TTP patient ( assessed 3 month presentation ) , ( iii ) safety toxicity Rituximab conjunction standard therapy acute TTP , ( iv ) effect Rituximab B cell function , ( v ) effect Rituximab ADAMTS 13 activity antibody production time relapse . The study design methodology devise specifically address question regard use Rituximab PEX improve treatment TTP patient least disruption inconvenience standard local treatment care decrease TTP patient mortality . Adult patient ( across 8 participate UK site ) present acute TTP fall within study protocol inclusion criterion , determine Lead Consultant Haematologist per institution , offer entry study . We wish recruit 40 patient study although incidence TTP low , generally consider diagnose therefore , underestimated . Recruiting 40 patient achievable consider number patient present acute TTP within SEE TTP study group past 18 month . Some TTP patient may unconscious may neurological dysfunction associate acute TTP , personality memory symptom . In case , consent request patient 's legal representative compliance International Conference Harmonisation ( ICH ) guidance Good Clinical Practice ( GCP ) . Given significant benefit term remission , increase level ADAMTS 13 level patient acute refractory TTP document benefit patient antibody driven disorder Rituximab therapy , Rituximab conjunction standard therapy - PEX , investigate . This reduce mortality 15-20 % , reduce number PEXs therefore decrease exposure blood component product may contain fatal protein variant Creutzfeldt-Jakob Disease ( vCJD ) . As 30-60 % relapse episode TTP , follow determine time relapse observe compare historical control . During period , blood count ADAMTS 13 level assess . We specific assay determine benefit follow treatment historical data compare previous patient admission match . Researcher bias reduce time take specific platelet level count ( 150 x 10 power 9/L ) must determine record within routine laboratory institution , number PEX record patient 's nurse , continue platelet count maintain 150 x 10 power 9/L . In addition , clear audit trail , allow data record cross check . The investigator know literature data collect part SEE TTP study group , epidemiology TTP mortality rate . With improvement laboratory technique , improve detection antibody ADAMTS 13 . As antibody ADAMTS 13 detect 90 % case , exclude specific precipitating cause , monitor ADAMTS 13 level ADAMTS 13 antibody make regularly research facility . As per patient 's local treatment protocol TTP i.e . PEX steroid treatment , patient daily PEX platelet level count &gt; 150 X 10 power 9/L . Patients receive pre-Rituximab medication ( Hydrocortison , Piriton , Paracetamol , per local protocol ) , 30 minute prior Rituximab infusion reduce potential side effect . Rituximab administer intravenously , immediately follow PEX . PEX withhold 24 hour follow Rituximab therapy , appropriate patient 's clinical condition . Rituximab give week 4 week first instance . The first treatment give within first 3 day admission , need administer Rituximab work office hour allow participate site obtain test result ascertain whether patient meet study 's inclusion criterion . If patient well enough discharge 4th treatment , treatment continue local haematology day unit . If still evidence antibody ADAMTS 13 ADAMTS 13 level corrected/normalised , maximum 4 additional Rituximab infusion give weekly . Nurses monitor patient 's blood pressure , pulse , breathe rate , temperature oxygen saturation level every 15 min first hour Rituximab infusion hourly infusion complete . The patient continue monitor per local protocol . The side effect Rituximab generally mild flu-like symptom , low blood pressure , nausea , flush rigor , experience , usually occur first infusion . Pre-medication note give prior Rituximab infusion . If side effect experience rate infusion review , slow suspend necessary intervention appropriate side effect give . Anaphylaxis potential risk first dose , patient receive appropriate pre-medication . Very rare side effect likely associate people extensive lymphoma disease and/or result several year use Rituximab clinical trial , primarily malignant disease , often chemotherapeutic agent well post marketing surveillance . All patient standard haematological biochemical blood test well ADAMTS 13 level assess . Regular blood test arrange patient discharged hospital , check full blood count , electrolytes liver function result ADAMDTS 13 level . TTP patient review initially weekly local out-patients clinic follow discharge time pass result stable period appointment lengthen . The study design cause least disruption inconvenience patient standard treatment/care . It imperative patient continuously assess monitor post study treatment . Any potential risk offset ( ) improve time remission , associate decreased time active TTP organ damage , ( ii ) reduce exposure plasma product thus risk vCJD ( iii ) improve management acute TTP mortality patient . All patient review local haematology clinic TTP clinic UCLH . Patients legal representative inform update TTP information general new information become available treatment/drug study regular outpatient consultation . Review ongoing data present SEE TTP study group well national international meeting . The final report present peer review journal . Patient also keep informed publication arise study hardcopies make available patient next kin/legal representative .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombotic Thrombocytopenic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients &gt; 18 year &lt; 65 year present acute episode TTP Evidence microangiopathic haemolytic anaemia Thrombocytopenia normal clot screen Raised Lactate Dehydrogenase ( one half time upper normal ) Patients without neurological dysfunction able give inform consent Patients reproductive age ( must avoid pregnancy 12 month and/or normalise B cell function receive Rituximab . Oestrogen contain oral contraceptive pill morning pill avoid female TTP patient ) Patients acute deterioration neurological function may include encephalopathy , altered personality , problem short term memory coma include consent give next kin appropriate legal representative . All female subject knowingly pregnant breast feeding use adequate form contraception ( effect foetus newborn yet fully establish Rituximab avoid group . Male patient receive Rituximab ensure adequate contraception 12 month follow treatment ) . Patients HIV positive ( appear antibody mediate , would unlikely benefit Rituximab ) Patients childhood TTP Patients Haemolytic Uraemic Syndrome ( HUS ) ( associate reduce ADAMTS 13 level ) Patients post bone marrow transplant either autologous allogeneic Patients wiht medical long term psychiatric condition , opinion investigator , contraindicate patient ' participation trial Previous concurrent malignancy sit , exception appropriately treat localized epithelial cervical cancer . Patients history cure tumour may enter ( &gt; 5 year ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>